Wuhan Keqian Biology Co.,Ltd (SHA:688526)
China flag China · Delayed Price · Currency is CNY
14.78
-0.25 (-1.66%)
May 12, 2026, 3:00 PM CST

SHA:688526 Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
May '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6,9737,0796,6369,50110,44312,805
Market Cap Growth
-5.69%6.68%-30.15%-9.03%-18.45%-33.80%
Enterprise Value
5,0995,3665,6358,2169,52210,651
Last Close Price
15.0315.2613.9119.4021.1425.76
PE Ratio
17.9016.9117.3624.0025.5022.44
Forward PE
14.6614.5113.5114.8616.9517.49
PS Ratio
7.487.457.058.9310.4311.61
PB Ratio
1.621.671.682.482.994.06
P/TBV Ratio
1.641.701.712.523.044.14
P/FCF Ratio
26.8520.5423.2221.9132.5581.65
P/OCF Ratio
18.4015.1116.9017.6624.6524.10
EV/Sales Ratio
5.475.655.987.729.519.66
EV/EBITDA Ratio
10.7511.1113.3217.4619.8316.68
EV/EBIT Ratio
14.1614.4517.8922.9924.8518.50
EV/FCF Ratio
19.6315.5719.7218.9529.6867.92
Debt / Equity Ratio
0.000.000.000.080.080.03
Debt / EBITDA Ratio
0.010.010.020.620.580.12
Debt / FCF Ratio
0.020.020.020.680.870.50
Net Debt / Equity Ratio
-0.43-0.56-0.49-0.39-0.47-0.39
Net Debt / EBITDA Ratio
-3.96-4.92-4.55-3.15-3.46-1.94
Net Debt / FCF Ratio
-7.21-6.90-6.74-3.42-5.18-7.89
Asset Turnover
0.200.210.210.240.250.32
Inventory Turnover
2.532.452.672.052.012.56
Quick Ratio
5.295.884.952.853.823.34
Current Ratio
7.426.405.343.384.113.58
Return on Equity (ROE)
9.26%10.19%9.81%10.78%12.30%19.47%
Return on Assets (ROA)
4.75%5.00%4.29%4.93%5.90%10.53%
Return on Invested Capital (ROIC)
14.55%16.57%12.55%14.74%17.90%39.80%
Return on Capital Employed (ROCE)
8.20%8.60%7.80%9.10%10.20%17.80%
Earnings Yield
5.59%5.92%5.76%4.17%3.92%4.46%
FCF Yield
3.73%4.87%4.31%4.56%3.07%1.23%
Dividend Yield
4.26%4.19%3.09%2.22%0.90%0.74%
Payout Ratio
51.19%47.64%53.51%24.52%22.83%23.97%
Buyback Yield / Dilution
-0.29%0.22%-0.10%-0.10%-0.29%-20.20%
Total Shareholder Return
4.01%4.42%2.99%2.12%0.61%-19.46%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.